Number of eligible patients: CDEC mentioned the uncertainty in the amount of patients with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or moderate disease can have a significant bleeding phe